Drug intelligence / Profile preview

HMPL-A830

Development stage: Phase 2
Lead developer: HUTCHMED
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HMPL-A830 is an investigational antibody-targeted therapy conjugate (ATTC) being developed by HUTCHMED. It utilizes the company's proprietary ATTC platform, which conjugates a small-molecule inhibitor payload to a monoclonal antibody to deliver a dual mechanism of action. As of March 2026, the candidate is in the preclinical stage, with HUTCHMED planning to submit global Investigational New Drug (IND) filings and initiate clinical trials later in 2026. Specific biological targets and therapeutic indications have not yet been publicly disclosed, though the platform is designed for next-generation targeted therapy solutions.

Beyond the preview

Go deeper on HMPL-A830.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HMPL-A830.

Explore the full profile